Home > News > Clinical trials put dendrimers on course for treating HIV
September 24th, 2003
Clinical trials put dendrimers on course for treating HIV
They might be nano’s artificial molecule, but dendrimers are taking real steps toward fighting HIV and sexually transmitted diseases in women. Starpharma Pooled Development Ltd. of Melbourne, Australia, gained approval in July from the U.S. Food and Drug Administration to start human trials of VivaGel, a dendrimer-based topical gel designed to prevent or reduce disease transmission during sexual intercourse. It’s the first dendrimer – and defined nanostructure – cleared for clinical testing, according to John Raff, Starpharma’s chief executive.
Speed at its limits September 30th, 2014
Ad-REIC vaccine: A magic bullet for cancer treatment September 30th, 2014
New Topical Hemostatic Agent: Neutral Self-Assembling Peptide Hydrogel September 30th, 2014
A Heartbeat Away? Hybrid "Patch" Could Replace Transplants: TAU researcher harnesses gold nanoparticles to engineer novel biocompatible cardiac patch September 30th, 2014